



PATIENT INFORMATION (Complete or Fax Existing Chart)		PRESCRIBER INFORMATION	
Name: _____ DOB: _____		Prescriber Name: _____	
Address: _____		State License: _____	
City, State, Zip: _____		NPI #: _____ Tax ID: _____	
Phone: _____ Alt. Phone: _____		Address: _____	
Email: _____ SS#: _____		City, State, Zip: _____	
Gender: <input type="checkbox"/> M <input type="checkbox"/> F Weight: _____ (lbs) Ht: _____		Phone: _____ Fax: _____	
Allergies: _____		Office Contact: _____ Phone: _____	
INSURANCE INFORMATION – AND – Send a copy of the patient's prescription/insurance cards (front & back)			
Primary Insurance: _____		Secondary Insurance (If Applicable): _____	
Plan #: _____		Plan #: _____	
Group #: _____		Group #: _____	
RX Card (PBM): _____		RX Card (PBM): _____	
BIN: _____ PCN: _____		BIN: _____ PCN: _____	
CLINICAL INFORMATION			
<input type="checkbox"/> G35.A Relapsing-remitting multiple sclerosis		<input type="checkbox"/> G35.B0 Primary progressive multiple sclerosis, unspecified	
<input type="checkbox"/> G35.C0 Secondary progressive multiple sclerosis, unspecified		<input type="checkbox"/> G35.C1 Active secondary progressive multiple sclerosis	
<input type="checkbox"/> G35.B1 Active primary progressive multiple sclerosis		<input type="checkbox"/> G35.B2 Non-active primary progressive multiple sclerosis	
<input type="checkbox"/> G35.D Multiple sclerosis, unspecified		<input type="checkbox"/> G35.CD Non-active secondary progressive multiple sclerosis	
<input type="checkbox"/> Other (Specify ICD-10 Code): _____			
Date of Last MRI: _____		Past DMT Therapies: _____	
Hepatitis B (HBsAg and anti-HBV) Test Results: <input type="checkbox"/> Positive <input type="checkbox"/> Negative		Quantitative Serum Immunoglobulins Test Results: _____	
Date of last treatment with an OCREVUS product (if applicable) (MM/DD/YYYY): _____/_____/_____			
ORDERS			
Prescription type: <input type="checkbox"/> New start <input type="checkbox"/> Restart <input type="checkbox"/> Continued therapy Total Doses Received: _____ Date of Last Injection/Infusion: _____			
Medication	Dose/Frequency	Quantity/Refills	
<input type="checkbox"/> OCREVUS ZUNOVO™ (920mg/23mL)	<input type="checkbox"/> 920 mg/23,000 units (920 mg ocrelizumab and 23,000 units of hyaluronidase) administered as a single 23 mL subcutaneous injection in the abdomen over approximately 10 minutes every 6 months <input type="checkbox"/> Other: _____	<input type="checkbox"/> Quantity: 1 Vial Refills: _____	
Pre-Medication	Dose/Strength	Directions	
<input type="checkbox"/> Acetaminophen	<input type="checkbox"/> 500mg	<input type="checkbox"/> Take 1-2 tablets PO prior to infusion or post-infusion as directed	
<input type="checkbox"/> Cetirizine	<input type="checkbox"/> 10mg	<input type="checkbox"/> Take 1 tablet PO prior to infusion or as directed	
<input type="checkbox"/> Dexamethasone	<input type="checkbox"/> 20mg	<input type="checkbox"/> Take 1 tablet PO prior to infusion or as directed	
<input type="checkbox"/> _____	_____	_____	
INFUSION REACTION ORDERS			
<b>Mild reaction protocol:</b>			
<input checked="" type="checkbox"/> Diphenhydramine 25mg IV, one time, for pruritus.			
<i>If symptoms worsen, see orders for moderate to severe reactions.</i>			
<b>Moderate reaction protocol:</b>			

CONFIDENTIALITY STATEMENT: This facsimile and documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender at the address and telephone number set forth herein and arrange for return or destruction of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.



- Acetaminophen 650mg PO, one time, for pyrexia or rigors
- Diphenhydramine 50mg IV, one time, for pruritus or urticaria
- Famotidine 20mg IV, one time, for, for pruritus or urticaria
- Methylprednisolone 125mg IV, one time, for respiratory or neurologic symptoms

*If symptoms worsen, see interventions for severe reactions*

**Severe reaction protocol: (Call 911 if initiated):**

- Titrate oxygen via continuous flow per nasal cannula or face mask to maintain spO2 of greater than ninety-five percent (>95%)
- Diphenhydramine 50mg IV, one time, for respiratory symptoms, edema, or anaphylaxis
- Methylprednisolone 125mg IV, one time, for respiratory symptoms, edema, or anaphylaxis
- Sodium Chloride 0.9% 500mL IV over 30-60 min, one time, for cardiovascular symptoms
- Epinephrine 0.3mg/0.3mL IM into mid-antrolateral aspect of thigh of anaphylaxis, may repeat x1 in 5-15 minutes if symptoms are not resolved or worsen

## FLUSHING & LOCKING ORDERS

### Flushing Protocol (>66lbs/33kg)

**PIV and Midline:**

- 0.9% Sodium Chloride 2-5mL IV flush before and after each infusion

**Implanted Port, PICC, Tunneled Catheter, and Non-tunneled Catheter:**

- 0.9% Sodium Chloride 5mL IV flush before infusion/lab draw and 10mL IV flush after infusion/lab draw

### Locking Protocol (>66lbs/33kg)

**PIV and Midline:**

- Heparin Sodium 10 units/mL 1mL IV final flush post normal saline flush

**PICC:**

- Heparin Sodium 10 units/mL 3mL IV final flush post normal saline flush

**Implanted Port, Tunneled Catheter, and Non-tunneled Catheter:**

- Heparin Sodium 100 units/mL 3-5mL IV final flush post normal saline flush

**\*\* May substitute Dextrose 5% in Water, or alternative, for 0.9% Sodium Chloride, when indicated due to incompatibility with medications being infused**

## SIGNATURE

We hereby authorize Talis Healthcare LLC to provide all supplies and additional services (nursing/patient training) required to provide and deliver the medicine as prescribed in this referral.

X \_\_\_\_\_

Prescriber Signature

Date: \_\_\_\_\_

To ensure payment by insurance carrier, please include supporting clinical documentation for specified ICD 10 Code, demographic, and insurance information along with faxed order. Initial appointment will be verified upon insurance approval.

CONFIDENTIALITY STATEMENT: This facsimile and documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender at the address and telephone number set forth herein and arrange for return or destruction of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.